Efficacy and Safety of Different Maintenance Doses of Caffeine Citrate for Treatment of Apnea in Premature Infants: A Systematic Review and Meta-Analysis

Jing Chen,1 Lu Jin,1 and Xiao Chen2

1Department of Neonatology, The First People's Hospital of Neijiang, Sichuan 641000, China
2Department of Orthopedic Surgery, The First People's Hospital of Neijiang, Sichuan 641000, China

Correspondence should be addressed to Xiao Chen; 342918992@qq.com

Introduction

Apnea is a common condition in premature infants due to the immaturity of respiratory control mechanisms [1]. Indeed, incidence increases with younger gestational age and lower birth weight, afflicting 25% of infants under 2500 g and 80% under 1000 g [2]. Recurrent apnea can lead to respiratory failure, pulmonary hemorrhage, abnormal heart and lung function, intracranial hemorrhage, abnormal nervous system development, and even sudden death [3, 4]. Therefore, the rate of disability and mortality of infants could be significantly reduced by early and effective clinical intervention [5, 6].

1. Introduction

At present, respiratory support and methylxanthine drugs such as theophylline, aminophylline, and caffeine are the main treatments for apnea of prematurity (AOP) [7, 8]. Caffeine has many potential advantages. It has a higher therapeutic ratio and fewer adverse reactions, is absorbed more reliably when administered enterally, and has a longer half-life than other methylxanthines. It is also effective in apneic infants unresponsive to theophylline [9, 10]. Thus, caffeine citrate has been used for the treatment of AOP in developed countries since the 1970s [11]. It was introduced in China in 2013 and has gradually replaced aminophylline as the preferred drug for AOP [12].
Although the curative efficacy of caffeine citrate for apnea treatment has been confirmed by several studies [13, 14], there is still substantial variation in the selection of maintenance dose for apnea treatment in premature infants due to the physiological particularities of this population, particularly hepatic and renal insufficiency and physical underdevelopment. Moreover, due to imperfect design and small sample size, previous studies on this issue are not convincing and no meta-analysis has been conducted on the safety and efficacy of different caffeine citrate maintenance doses for AOP. Therefore, the aims of this meta-analysis are to evaluate the efficacy and safety of low and high caffeine citrate maintenance doses for AOP treatment of premature infants by pooled analysis of existing clinical studies.

2. Methods

2.1. Data Sources and Searches. We searched for all relevant studies in the PubMed, Cochrane Library, OVID, Embase, Web of Science, Chinese Biomedical Literature, Weipu Journal, Wanfang, and CNKI databases published from inception to September 2018. The search strategy combined two areas as MeSH terms, keywords, and text words using Boolean operators: (i) “infant, premature [MeSH]” OR “infants, premature” OR “premature infant” OR “premature infants” OR “preterm infants” OR “preterm infant” OR “premature” OR “infants, preterm” OR “infant, preterm” OR “infants, preterm” OR “neonatal prematurity” OR “prematurity, neonatal”; AND (ii) “apnea [MeSH]” AND (iii) “caffeine [MeSH]” OR “1,3,7-Trimethylxanthine” OR “Vivarin” “caffedrine” OR “coffeinum” AND “dose”. Google Scholar was also searched to identify potentially relevant literature. In addition, the reference lists of included studies and all related review articles were checked for additional trials, published or unpublished. The search was limited to randomized controlled trials (RCTs) published in English or Chinese.

2.2. Study Selection. Studies were selected based on the following inclusion criteria. (i) Patients: participants were medically diagnosed with AOP and (first case) were younger than 37 weeks’ gestational age at birth with typical apnea episode duration longer than 20 seconds or (second case) demonstrated typical apnea episodes shorter than 20 seconds but with heart rate < 100 beats/minute (bpm) or blue skin, hypoxemia, and hypotonia [15]. (ii) Interventions: all patients were given a load dose (no limits), then changed to a maintenance dose of caffeine citrate after 24 hours administered once daily by intravenous infusion and stopped 7 days after mitigation of apnea. The high dose group (HD group) received a maintenance dose of 10–20 mg/kg/day while the LD group was treated with a maintenance dose of 5–10 mg/kg/day. (iii) Outcomes: (1) primary outcomes were (a) rate of effective treatment, defined as successful evacuation within 72 hours after treatment onset, fewer than 3 apnea episodes per day, and no significant abnormalities in respiratory rhythm, (b) adverse effects such as tachycardia, electrolyte disturbance, hypertension, hyperglycemia, feed intolerance, and restlessness, and (c) in-hospital mortality. (2) Secondary outcomes were success rate of ventilator removal, extubation failure rate, frequency of apnea, apnea duration, and complications (bronchopulmonary dysplasia [BPD], retinopathy of prematurity [ROP], necrotizing enterocolitis [NEC], intraventricular hemorrhage [IVH], and periventricular leukomalacia [PVL]). (iv) Study design: only prospective RCTs were considered.

Exclusion criteria were as follows: (1) retrospective studies, cohort studies, single-case reports, animal studies, reviews, meta-analyses, posters, or abstracts; (2) study objective or intervention measures failed to meet the inclusion criteria; (3) duplicate or multiple publications of the same study; (4) studies without usable data.

2.3. Data Extraction and Quality Assessment. The abstracts of retrieved studies were independently reviewed by two authors (Jing Chen and Lu Jin) and full articles were examined when necessary. The data were extracted independently by these two authors and any disagreements were resolved by discussion with at least one more author (Xiao Chen) until a consensus was reached. If more than one article was published from the same cohort, the study with the most comprehensive data was selected for inclusion.

The following data was extracted: general information (first author, country of origin, publication date, number of total cases, number of males and females, mean ages, interventions, and follow-ups) and outcomes (as defined above).

Risk of bias for each study was assessed using the Cochrane Risk of Bias Tool. Bias was assessed as a judgment (high, low, or unclear) for seven domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias.

2.4. Data Synthesis and Analysis. The data were pooled using Review Manager 5.3 software. Risk ratios (RRs) were calculated for dichotomous variables in each study. Weighted mean difference (WMD) was calculated for continuous variables, and 95% confidence intervals (CIs) were determined for all effect sizes. Heterogeneity of the included studies was evaluated using Higgins I$^2$. A random-effect model was used when apparent heterogeneity was detected ($I^2 \geq 50\%$, $P<0.05$). Otherwise, a fixed effect model was used ($I^2 < 50\%$, $P\geq0.05$). Potential publication bias was judged by Begg’s or Egger’s tests. Sensitivity analysis was performed to determine the robustness of the combined data. A p-value < 0.05 was regarded as statistically significant.

3. Results

The initial literature search identified 345 citations. After removal of duplicates, 102 studies were screened for eligibility. Of these, 79 were excluded based on title and abstract review, leaving 23 full-text articles for full-text evaluation. An additional 10 studies that failed to meet the inclusion criteria were excluded, leaving 13 RTCs [16–28] for inclusion (Figure 1).
The main characteristics of these studies are summarized in Table 1. Five studies were written in English and the other eight in Chinese. According to the Cochrane Collaboration Risk of Bias Tool, the quality of all RCTs was acceptable as all reported the method of randomization (Figure 2). Six RCTs were conducted using computer-generated lists, two used sealed envelopes, and 5 reported blinding of the doctors and participants. No trial showed an unclear bias due to incomplete outcome data or selective outcome reporting.

3.1. Meta-Analysis on Efficacy of Intervention

3.1.1. The Effective Rate. Six articles with a total of 413 infants reported the relevant data regarding efficacy rate of caffeine treatment. Data pooling revealed a significantly higher effective rate in the HD group compared to the LD group (RR: 1.37, 95%CI: 1.18 to 1.60, P<0.0001; Figure 3(a)). Sensitive analysis after excluding the outlier study also revealed a significant difference between HD group and LD group for the remaining studies with low statistical heterogeneity (RR: 1.31, 95%CI: 1.18 to 1.45, P<0.00001, I²=0%; Figure 3(b)).

3.1.2. Adverse Effects. A total of 8 studies reported the incidence of tachycardia (435 infants in the HD group and 445 in the LD group). The incidence of tachycardia was significantly higher in the HD group than the LD group (RR: 2.02, 95%CI: 1.30 to 3.12, P=0.002; Figure 4). In contrast, there were no statistically significant differences in other adverse effects such as electrolyte disturbance, hypertension, hyperglycemia, feeding intolerance, and restlessness (P>0.05; Figure 5).

3.1.3. Hospital Mortality. Data on hospital mortality were available in eight articles including 1064 infants. Data pooling revealed no significant difference between groups (RR: 0.74, 95%CI: 0.51 to 1.09, P=0.13; Figure 6).

3.1.4. The Success Rate of Removal of Ventilator and Extubation Failure Rate. Three studies reported success rate of ventilator removal, and data pooling showed that the rate was significantly higher in the HD group than the LD group (RR: 1.74, 95%CI: 1.04 to 2.90, P=0.03; Figure 7). Three trials reported the extubation failure rate, and pooled results revealed a
significantly lower extubation failure rate in the HD group compared to the LD group (RR: 0.5, 95% CI: 0.35 to 0.71, P=0.0001; Figure 8).

3.1.5. Frequency of Apnea and Apnea Duration. Only 2 trials with 168 infants reported the frequency of apnea and apnea duration. The HD group demonstrated a significantly lower frequency of apnea and shorter apnea duration than the LD group (MD: -1.55, 95% CI: -2.72 to -0.39, P=0.009, Figure 9; MD: -4.85, 95% CI: -8.29 to -1.40, P=0.006; Figure 10).

3.2. Complications. A total of 9 articles reported the incidence of bronchopulmonary dysplasia (531 infants in the HD group and 553 in the LD group). Pooled data revealed a significantly lower incidence in the HD group (RR: 0.79, 95% CI: 0.68 to 0.91, P=0.002; Figure 11). There were no statistically significant differences in the frequencies of other complications (Table 2), such as ROP, NRC, IVH, and PVL (P>0.05).

3.3. Publication Bias. Begg’s plots are presented in Figures 12–14. Test results provided no evidence of publication bias (P_{Begg}=0.917 for BPD, Figure 12; P_{Begg}=1.000 for tachycardia, Figure 13; P_{Begg}=0.536 for hospital mortality, Figure 14).

3.4. Sensitivity Analysis. Sensitivity analysis indicated that our current data were relatively steady and credible (Figures 15–17).
4. Discussion

At present, caffeine is the first choice for AOP treatment [8]. However, the maintenance dose has not been standardized [29]. Therefore, several [16–18, 20, 23] studies have examined the efficacy of different doses of caffeine for maintenance therapy of premature infants. Charles et al. reported a substantially lower extubation failure rate in a high maintenance dose group compared to a low maintenance dose group (17% versus 49%, P<0.05) as well as significantly reduced average mechanical ventilation time in the high-dose group (P<0.01) [30]. However, Mohammed et al. found that a high
maintenance dose of caffeine citrate was more likely to cause adverse reactions such as tachycardia [20]. Thus, although a higher maintenance dose can improve the clinical efficiency against AOP, it may also increase the frequency of adverse reactions. At present, there is no definitive evidence from a systematic review and meta-analysis to support which maintenance dose is superior considering both efficacy and safety.

Whether the treatment is effective or not is the focus of clinicians’ attention. This meta-analysis found that a higher maintenance dose of caffeine citrate (10–20 mg/kg daily) was significantly more efficacious against AOP, enhanced the success rate of ventilator removal, and decreased the extubation failure rate, apnea frequency, apnea duration, and incidence of BPD compared to a lower dose (5–10 mg/kg daily). With regard to the effective rate, sensitive analysis after excluding
Figure 6: Forest plot of hospital mortality between HD group and LD group.

Figure 7: Forest plot of the success rate of ventilator removal between HD group and LD group.

Figure 8: Forest plot of the extubation failure rate between HD group and LD group.

Figure 9: Forest plot of the frequency of apnea between HD group and LD group.
the outlier study also revealed a significant difference between HD group and LD group for the remaining studies with low statistical heterogeneity. Similarly, Turmen [31] found that ventilation volume per minute increased rapidly and reached a stable level in the subsequent ventilation reaction following higher maintenance doses of caffeine citrate (reaching higher blood concentrations) to premature infants. Thus, a high maintenance dose of caffeine appears more effective for promoting lung maturation in premature infants, consistent with the current results on AOP treatment.

Nonetheless, some clinicians [16–18, 20, 23] are still wary of administering large maintenance doses due to the risks of adverse reactions. Indeed, this meta-analysis found a higher incidence of tachycardia in the HD group. However, the reasons for caffeine citrate treatment are to stimulate the central nervous system, improve autonomic nerve function, promote myocardial contraction, and dilate blood vessels, which will result in increased cardiac output and blood pressure [32]. In clinical practice, children who cannot tolerate caffeine could be treated by drugs to improve tachycardia or receive a lower
Table 2: Other complications.

| No. of trials | HD         | LD         | I² | Effect-Model | Outcomes | P     |
|---------------|------------|------------|----|--------------|----------|-------|
| ROP           | 2          | 0.74[0.52, 1.05] | 0.09 | Fixed        |          |       |
| NEC           | 4          | 0.54[0.26, 1.12] | 0.10 | Fixed        |          |       |
| IVH           | 7          | 0.98[0.76, 1.27] | 0.89 | Fixed        |          |       |
| PVL           | 3          | 1.35[0.59, 3.07] | 0.47 | Fixed        |          |       |

Figure 14: Funnel plot for publication bias test for hospital mortality.

Figure 15: Sensitivity analysis of BPD for high versus low maintenance dose.

Figure 16: Sensitivity analysis of tachycardia for high versus low maintenance dose.

Figure 17: Sensitivity analysis of hospital mortality for high versus low maintenance dose.

We found that Begg’s Test results provided no evidence of publication bias about BPD, tachycardia, and hospital mortality. Sensitivity analysis was performed to determine the robustness of the combined data. And our meta-analysis found that the sensitivity analysis of BPD, hospital mortality, and tachycardia for high versus low maintenance dose were relatively steady and credible.

However, some limitations of this study should be acknowledged. First, the maintenance dose varied within the high- and low-dose range, which may have obscured group differences in outcomes or complication rates. Second, there were no reports on long-term outcomes such as intellectual development. Third, there were too few trials in this meta-analysis to assess some outcomes such as the success rate of removal of ventilator, extubation failure rate, frequency of apnea, apnea duration, and other rare adverse reactions. Fourth, most of the studies included are in Chinese, and the
quality score is relatively low, which affects the credibility of this outcome to some extent. Therefore, more trials of high quality, multicenter, and large sample size will be included in the future. Last, we failed to assess the heterogeneity of infants regarding neonatal weight, gender, gestational age, or other factors between studies. To compensate for this deficiency, we will assess the heterogeneity of these factors in our next meta-analysis.

This meta-analysis showed that a high maintenance dose of caffeine citrate (10–20 mg/kg daily) is more effective than and at least as safe as a lower maintenance dose (5–10 mg/kg daily) for the treatment of AOP. However, owing to the limited quantity and quality of available RTCs, further study is needed to confirm these findings.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

References

[1] J. Zhao, F. Gonzalez, and D. Mu, “Apnea of prematurity: From cause to treatment,” European Journal of Pediatrics, vol. 170, no. 9, pp. 1097–1105, 2011.
[2] C. M. T. Robertson, M.-J. Watt, and J. A. Dinu, “Outcomes for the extremely premature infant: what is new? and where are we going?” Pediatric Neurology, vol. 40, no. 3, pp. 189–196, 2009.
[3] L. L. Spriet, “Exercise and sport performance with low doses of caffeine,” Sports Medicine, vol. 44, pp. 175–184, 2014.
[4] I. Ulansky, N. S. Haleluya, S. Blazer, and A. Weissman, “The effects of caffeine on heart rate variability in newborns with apnea of Prematurity,” Journal of Perinatology, vol. 34, no. 8, pp. 620–623, 2014.
[5] S. J. Francart, M. K. Allen, and J. Stegall-Zanation, “Apnea of prematurity: caffeine dose optimization,” The Journal of Pediatric Pharmacology and Therapeutics, vol. 18, no. 1, pp. 45–52, 2013.
[6] B. Schmidt, P. J. Anderson, L. W. Doyle et al., “Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity,” Journal of the American Medical Association, vol. 307, no. 3, pp. 275–282, 2012.
[7] P. J. Johnson, “Caffeine citrate therapy for apnea of prematurity,” Neonatal Network, vol. 30, no. 6, pp. 408–412, 2011.
[8] A. Erenberg, R. D. Leff, D. G. Haack, K. W. Moddell, G. M. Hicks, and B. A. Wynne, “Caffeine citrate for the treatment of apnea of prematurity: a double-blind, placebo-controlled study,” Pharmacotherapy, vol. 20, no. 61, pp. 644–652, 2000.
[9] R. K. Philip, A. Ismail, B. Murphy, A. Mirza, C. Quinn, and M. Dunworth, “Caffeine treatment for apnea of prematurity and the influence on dose-dependent postnatal weight gain observed over 15 years,” Journal of Caffeine and Adenosine Research, vol. 8, no. 3, pp. 99–106, 2018.
[10] B. Shrestha and G. Jawa, “Caffeine citrate – Is it a silver bullet in neonatology?” Pediatrics and Neonatology, vol. 58, no. 5, pp. 391–397, 2017.
[11] B. Schmidt, R. S. Roberts, P. Davis et al., “Long-term effects of caffeine therapy for apnea of prematurity,” The New England Journal of Medicine, vol. 357, no. 19, pp. 1893–1902, 2007.
[12] H. Abdel-Hady, “Caffeine therapy in preterm infants,” World Journal of Clinical Pediatrics, vol. 4, no. 4, p. 81, 2015.
[13] P. A. Steer and D. J. Henderson-Smart, “Caffeine versus theophylline for apnea in preterm infants,” Cochrane Database of Systematic Reviews (Online), no. 2, p. CD000273, 2010.
[14] D. J. Henderson-Smart and A. G. De Paoli, “Methylxanthine treatment for apnoea in preterm infants,” Cochrane Database of Systematic Reviews, vol. 12, 2010.
[15] N. N. Finer, R. Higgins, J. Kattwinkel, and R. J. Martin, “Summary proceedings from the apnoea-of-prematurity group,” Pediatrics, vol. 117, no. 3, pp. S47–S51, 2006.
[16] S. Z. Xu, X. Y. Hu, F. Zhao et al., “Effect of different maintenance doses caffeine for apnea of preterm,” Journal of Pediatric Health Care, vol. 22, no. 09, pp. 14–16, 2016.
[17] Y. Zhao, X. Tian, and G. Liu, “Clinical effectiveness of different doses of caffeine for primary apnea in preterm infants,” Zhonghua er ke za zhi = Chinese journal of pediatrics, vol. 54, no. 1, pp. 33–36, 2016.
[18] Z. A. Vescoulsis, C. McPherson, J. I. Neil, A. M. Mathur, and T. E. Inder, “Early High-Dose Caffeine Increases Seizure Burden in Extremely Preterm Neonates: A Preliminary Study,” Journal of Caffeine Research, vol. 6, no. 3, pp. 101–107, 2016.
[19] P. H. Gray, V. J. Flenady, B. G. Charles, and P. A. Steer, “Caffeine citrate for very preterm infants: Effects on development, temperament and behaviour,” Journal of Paediatrics and Child Health, vol. 47, no. 4, pp. 167–172, 2011.
[20] S. Mohammed, I. Nour, A. E. Shabaan, B. Shouman, H. Abdel-Hady, and N. Nasef, “High versus low-dose caffeine for apnea of prematurity: a randomized controlled trial,” European Journal of Pediatrics, vol. 174, no. 7, pp. 949–956, 2015.
[21] P. Steer, “High dose caffeine citrate for extubation of preterm infants: a randomised controlled trial,” Archives of Disease in Childhood - Fetal and Neonatal Edition, vol. 89, no. 6, pp. F499–F503, 2004.
[22] J. E. M. Scanlon, K. C. Chin, M. E. I. Morgan, G. M. Durbin, K. A. Hale, and S. S. Brown, “Caffeine or theophylline for neonatal apnoea?” Archives of Disease in Childhood, vol. 67, no. 4, pp. 425–428, 1992.
[23] S. K. Chaudhari, H. Y. Chen, and J. F. Tan, “The study of different doses of caffeine and aminophylline treatment for apnea of premature infants,” Chinese Journal of Neonatology, vol. 31, no. 05, pp. 348–352, 2016.
[24] Y. E. Zhu, C. Y. Mo, and L. Y. Ao,” The influence of different doses of caffeine in treatment of premature infants with primary apnea adverse reactions and clinical results,” Journal of North Pharmacy, vol. 14, no. 02, pp. 154-155, 2017.
[25] L. P. Zhang, “Selection and analysis of caffeine citrate dosage for apnea of prematurity,” Stratt Pharmaceutical Journal, vol. 29, no. 03, pp. 135-136, 2017.
[26] Y. Xue, “Effects of different doses of caffeine on clinical outcomes in children with primary apnea,” Henan Medical Research, vol. 26, pp. 1498-1499, 2017.
[27] J. H. Song, J. T. Wang, and S. T. Tang, “Clinical observation of different doses of caffeine citrate in treating premature infants with apnea,” Shenzhen Journal of Integrated Traditional Chinese, vol. 27, no. 07, pp. 150-151, 2017.
[28] C. Y. Wu, X. J. Jia, and Y. H. Bai, “Therapeutic effect of caffeine citrate on neonatal apnea,” Journal of Changzhun University of Traditional Chinese Medicine, vol. 32, no. 03, pp. 622–624, 2016.
[29] N. L. Maitre, J. Chan, A. R. Stark, W. E. Lambert, J. L. Ashchner, and A. P. Key, “Effects of caffeine treatment for apnea of
prematurity on cortical speech-sound differentiation in preterm infants,” *Journal of Child Neurology*, vol. 30, no. 3, pp. 307–313, 2015.

[30] B. G. Charles, S. R. Townsend, P. A. Steer, V. J. Flenady, P. H. Gray, and A. Shearman, “Caffeine citrate treatment for extremely premature infants with apnea: Population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring,” *Therapeutic Drug Monitoring*, vol. 30, no. 6, pp. 709–716, 2008.

[31] T. Turmen, J. Davis, and J. V. Aranda, "Relationship of dose and plasma concentrations of caffeine and ventilation in neonatal apnea," *Seminars in Perinatology*, vol. 5, no. 4, pp. 326–331, 1981.

[32] A. R. Merrikhi, S. Ghaemi, A. Gheissari, M. Shokrani, Y. Madihi, and F. Mousavinasab, "Effects of aminophylline in preventing renal failure in premature neonates with asphyxia in Isfahan-Iran.," *JPMA. The Journal of the Pakistan Medical Association*, vol. 62, no. 3, pp. S48–51, 2012.